Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $2.03, but opened at $2.11. Autolus Therapeutics shares last traded at $2.04, with a volume of 118,877 shares.

Wall Street Analyst Weigh In

A number of brokerages have commented on AUTL. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Performance

The company has a market capitalization of $518.88 million, a PE ratio of -1.61 and a beta of 2.02. The firm’s 50-day simple moving average is $2.24 and its 200-day simple moving average is $3.21.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its holdings in shares of Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares in the last quarter. FMR LLC increased its stake in Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Candriam S.C.A. purchased a new stake in shares of Autolus Therapeutics in the 4th quarter valued at $7,500,000. AXA S.A. purchased a new stake in shares of Autolus Therapeutics in the 4th quarter valued at $4,288,000. Finally, Millennium Management LLC boosted its holdings in shares of Autolus Therapeutics by 91.6% in the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company’s stock valued at $3,885,000 after acquiring an additional 790,437 shares during the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.